Retinal Vascular Reactivity in Subjects With Newly Diagnosed Glaucoma Before and After Selective Laser Trabeculoplasty
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01209975|
Recruitment Status : Unknown
Verified September 2010 by University of Toronto.
Recruitment status was: Recruiting
First Posted : September 28, 2010
Last Update Posted : September 28, 2010
|Condition or disease||Intervention/treatment|
|Glaucoma||Procedure: Selective Laser Trabeculoplasty|
|Study Type :||Observational|
|Estimated Enrollment :||12 participants|
|Official Title:||Retinal Vascular Reactivity in Response to Isoxic Hypercapnia in Subjects With Newly Diagnosed Glaucoma|
|Study Start Date :||November 2008|
|Estimated Primary Completion Date :||November 2011|
untreated glaucoma patients
We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
Procedure: Selective Laser Trabeculoplasty
Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
- blood flow [ Time Frame: before and two-week after SLT ]The Canon Laser Blood Flowmetry will be used to assess the retinal blood flow.
- Intraocuclar pressure [ Time Frame: before and two-week after SLT ]Intraocular pressure (IOP) will be measured by Goldmann applanation tonometry.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01209975
|Contact: Tien Wongemail@example.com|
|Toronto Western Hospital||Recruiting|
|Toronto, Ontario, Canada, M5T2S8|
|Contact: Tien Wong 416-603-5694 firstname.lastname@example.org|
|Principal Investigator:||Chris Hudson, PhD||University of Toronto|